381 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
251 | 18805633 | The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. | 2009 Jan 18 | 2 |
252 | 19042015 | The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. | 2009 Feb | 5 |
253 | 19118059 | Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. | 2009 Jan 1 | 1 |
254 | 19228734 | Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. | 2009 Feb 15 | 7 |
255 | 19258951 | Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. | 2009 Jan | 4 |
256 | 19295274 | [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response]. | 2009 Mar | 2 |
257 | 19331197 | Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. | 2009 Feb | 1 |
258 | 19372587 | ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. | 2009 Apr | 5 |
259 | 19632322 | Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. | 2009 Oct 8 | 4 |
260 | 19691751 | Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. | 2009 Aug | 2 |
261 | 19720916 | Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. | 2009 Oct 1 | 1 |
262 | 19755824 | [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer]. | 2009 Sep | 1 |
263 | 19794992 | Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. | 2009 Oct | 3 |
264 | 19858400 | Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. | 2009 Nov 20 | 1 |
265 | 19887543 | A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. | 2009 Nov | 3 |
266 | 19918289 | Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. | 2009 Sep 15 | 1 |
267 | 20062660 | Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. | 2009 Dec 4 | 1 |
268 | 17468948 | HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. | 2008 Mar | 2 |
269 | 17953985 | Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. | 2008 Feb | 1 |
270 | 18364725 | HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy. | 2008 May | 1 |
271 | 18365200 | Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. | 2008 Nov | 1 |
272 | 18375893 | Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. | 2008 Apr 1 | 2 |
273 | 18685414 | Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. | 2008 Sep | 2 |
274 | 18766004 | Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. | 2008 Oct | 4 |
275 | 18955454 | Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. | 2008 Dec 1 | 2 |
276 | 18985033 | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. | 2008 Dec 2 | 1 |
277 | 19106581 | [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel]. | 2008 Nov | 1 |
278 | 16850247 | Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. | 2007 Mar | 1 |
279 | 17200359 | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. | 2007 Jan 1 | 2 |
280 | 17220672 | [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response]. | 2007 Jan | 1 |
281 | 17343796 | [Apoptotic effect of the combined treatment of engineered antibody with paclitaxel on BT474 cells]. | 2007 Mar | 6 |
282 | 17465239 | Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. | 2007 Mar-Apr | 2 |
283 | 17586082 | Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. | 2007 Jul 31 | 1 |
284 | 17647266 | Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. | 2007 Sep 15 | 1 |
285 | 17660958 | The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. | 2007 Feb | 3 |
286 | 17828616 | Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. | 2007 Dec | 3 |
287 | 17879382 | Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1. | 2007 Nov | 4 |
288 | 17928597 | HER2 and response to paclitaxel in node-positive breast cancer. | 2007 Oct 11 | 4 |
289 | 17987122 | HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. | 2007 Nov 7 | 1 |
290 | 18022396 | Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. | 2007 Dec 22 | 1 |
291 | 18038883 | When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? | 2007 Sep-Oct | 1 |
292 | 18083698 | Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. | 2007 Dec | 1 |
293 | 18086299 | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. | 2007 | 1 |
294 | 16467098 | Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. | 2006 Feb 1 | 1 |
295 | 16580691 | 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. | 2006 May 15 | 4 |
296 | 16764747 | Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression. | 2006 Apr | 1 |
297 | 16782917 | Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. | 2006 Jun 20 | 1 |
298 | 16847284 | Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. | 2006 Aug 10 | 1 |
299 | 16969027 | [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy]. | 2006 Sep | 3 |
300 | 17146157 | Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience. | 2006 | 1 |